Double-Punch cancer treatment shows promise in early trials
NCT ID NCT04257578
First seen Nov 01, 2025 · Last updated Apr 21, 2026 · Updated 26 times
Summary
This study is testing whether combining two different cancer treatments works better than either alone for people with B-cell lymphoma. The trial combines a targeted drug (acalabrutinib) with engineered immune cells (CAR-T therapy) that are designed to attack lymphoma cells. Researchers are checking if this combination is safe and effective for adult patients with various types of B-cell lymphoma who meet specific treatment criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.